San Francisco-based Osanni Bio LLC has closed a USD 190 million Series B financing round to advance its multi-therapeutic platform, with active programs in ophthalmology, cardiology, and additional undisclosed areas. The round was led by Patient Square Capital, a dedicated healthcare investment firm with USD 19 billion in assets under management.
Existing investors the Horowitz Group, Invus Opportunities, and the Retinal Degeneration Fund participated alongside the lead investor. The company said proceeds will be used to advance its current pipeline of multiple programs and scale its discovery and development process. No prior funding rounds were disclosed in the announcement, making this the first publicly confirmed capital raise for Osanni Bio.
Osanni Bio's model centers on a centralized innovation engine designed to identify scientific insights, generate novel drug concepts, and advance programs to proof-of-concept. Once a program is sufficiently de-risked, it graduates into an ecosystem of affiliate companies that are structured to provide focused development capabilities and specialized talent. The company frames this architecture as combining the scientific depth of a centralized platform with the operational agility of independent companies — an approach it says is optimized for capital efficiency.
The participation of the Retinal Degeneration Fund among existing investors suggests the company's ophthalmology programs may include retinal disease as a focus area, though Osanni has not publicly disclosed specific targets or indications for any of its pipeline assets. No clinical stage or regulatory milestone information was provided.
Patient Square Capital's Founding Partner Neel Varshney, M.D., described the investment as supporting "a new model for discovering and developing innovative medicines," citing the company's pairing of scientific depth with capital efficiency as a key rationale for the firm's involvement. Patient Square, which focuses exclusively on healthcare, has backed growth-oriented companies across the sector.
The USD 190 million raise is a substantial commitment for a development-stage platform company that has not yet disclosed specific drug candidates or clinical data. The size of the round and the involvement of a dedicated healthcare private equity firm suggest investor confidence in both the platform model and the management team's prior track record, even in the absence of publicly available pipeline details.